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What is the best way 
to diagnose menopause?
■ Evidence summary
Since natural menopause is clinically
defined as the final menstrual period, the
best way to diagnose it is to retrospectively
observe 12 consecutive months of amenor-
rhea. Several studies followed women longi-
tudinally and found the characteristics that
best predicted actual transition to
menopause within 4 years were amenorrhea
of between 3 and 12 months duration (sen-
sitivity=0.16–0.32; specificity=0.98–1.0;
positive likelihood ratio [LR+]=14.4–∞;
negative likelihood ratio [LR–]=0.69–0.84),
cycle irregularity within 12 months (sensi-
tivity=0.65–0.66; specificity=0.77–0.85;
LR+ =2.84-4.17; LR– =0.42–0.84), and age
≥50 years (sensitivity=0.35; specifici-
ty=0.98; LR+ =15.4; LR– =0.66).1–3 Change
in the amount of flow is more sensitive but
less specific (sensitivity=0.81; specifici-
ty=0.30; LR+ =1.15; LR– =0.65).3 A
woman’s global perception of being peri-
menopausal can also be useful for “ruling-
in” transition to menopause within the next
several years (sensitivity=0.18; specificity=1;
LR+ =∞; LR– =0.82).1,5 No studies were
identified that prospectively studied the use-
fulness of laboratory or radiologic findings
C L I N I C A L C O M M E N T A R Y
Take an active approach, reassure patients they
are experiencing a normal transition 
Women usually come to our practice when 
they start experiencing perimenopausal symptoms
and seek relief. After ruling out clinically similar
conditions like diabetes or thyroid disease, we can
take an active approach of patient education. We
reassure patients that they are experiencing a 
normal hormonal transition that can take 6 to 7
years. It is important to emphasize any needed
lifestyle changes in such areas as smoking, sub-
stance use, diet and exercise, weight management,
bone loss prevention, and bladder control. We can
discuss with our patients ways of alleviating 
symptoms. In our practice, we do not frequently
use hormonal lab tests (FSH, luteinizing hormone,
estrogen), since they can be unreliable and do not
usually affect our clinical approach. In addition to
the perimenopausal syndrome, diagnosing the
patient’s condition as “menopause” only describes
cessation of fertility. We encourage women to use
safe methods of contraception until they experience
12 months of amenorrhea. Before that time, 
barrier methods (IUDs, condoms, etc) are options
of choice, since oral contraceptives may mask 
perimenopausal symptoms and invalidate any 
hormonal measurements.
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No single test for menopause is highly sensitive
and specific. The best predictors that a woman will
enter menopause within 4 years include age at
least 50 years, amenorrhea for 3 to 11 months, and
menstrual cycle irregularity within 12 months
(strength of recommendation [SOR]: B; based on
multiple prospective cohort studies). 
For diagnosing perimenopause, the level of fol-
licle-stimulating hormone (FSH) is most useful for
clinical situations in which the pretest probability,
as based on history, is midrange (SOR: B, based on
1 systematic review and 2 cross-sectional studies).
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For diagnosing
perimenopause,
FSH level is most
useful when 
the pretest 
probability is
midrange
FAST TRACK
T A B L E
SYMPTOM/LAB TEST SENSITIVITY SPECIFICITY LR+ LR–
Elevated FSH*4,6,7 0.65–0.74 0.79–0.94 3.06–11.32 0.29–0.45
Inhibin (immunoreactive)4 0.07 0.96 1.90 0.97
Inhibin A4 0.61 0.54 1.31 0.73
Inhibin B4 0.46 0.78 2.05 0.70
Hot flashes1,4 0.22–0.59 0.83–0.91 2.12–4.06 0.54–0.87
Night sweats4 0.20–0.50 0.74–0.87 1.90 0.67–0.92
Vaginal dryness4 0.11–0.29 0.80–0.97 1.48–3.79 0.92
Self-perceived 0.77–0.95 0.39–0.64 1.53–2.13 0.10–0.36
perimenopausal status1,4
LR+, likelihood ratio if the test is positive; LR–, likelihood ratio if the test is negative; 
FSH, follicle-stimulating hormone.
*Two studies defined elevated FSH as ≥20 IU/L, one study defined elevated FSH as ≥24 IU/L. 
Symptoms and laboratory tests for diagnosing perimenopause
among perimenopausal women for predict-
ing transition to postmenopausal state. 
Because the perimenopause marks the
entry into the menopausal transition,
whether a woman has entered peri-
menopause is often the more relevant diag-
nosis to be made. Factors often used to
diagnose perimenopause include age,
maternal age at menopause, vasomotor
and vaginal symptoms, FSH level, and a
patient’s global perception of being peri-
menopausal. Other proposed methods
include vaginal ultrasound to measure
ovarian volume and number of antral fol-
licles and assays for inhibins, but currently
the test characteristics for these are inferior
to less invasive and less costly methods. 
Age alone can be a useful predictor for
perimenopause; most women have either
entered or completed the menopausal tran-
sition by age 50, and almost all by age 55. 
The TABLE summarizes test character-
istics for a variety of symptoms and lab
assays to diagnose perimenopause. No one
test is highly sensitive and specific. Typical
symptoms of hot flashes, night sweats, and
vaginal dryness are about as specific as lab-
oratory tests, but are generally less sensi-
tive.1,4,6–7 Self-perceived menopausal status
is moderately to highly sensitive, but the
range of specificity estimates are wide. The
LR+ and LR– for FSH, which are of mid-
high magnitude, would suggest it to be the
best single diagnostic test.4,6,7 However,
because laboratory tests are usually
ordered after some determination of
pretest probability based on history and
physical, FSH may be of less utility where
the pretest probability for perimenopause
is already high, such as the case of a 52-
year-old woman seeking “confirmation”
for perimenopausal symptoms. FSH levels
are highly varied within individuals during
perimenopause; and further variation due
to body-mass index and ethnicity make
defining diagnostic thresholds difficult.8
Recommendations from others
The American Academy of Family
Physicians, American College of Physicians,
and American College of Obstetricians and
Gynecologists do not address the diagnosis
of menopause in any recommendations.
The North American Menopause
Society states that estradiol and FSH are of
limited value in confirming perimenopause
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due to extreme monthly fluctuations. They
say perimenopausal women are not pro-
tected from unplanned pregnancy until
amenorrhea of at least 1 year’s duration or
consistently elevated FSH levels (>30 IU/L)
are demonstrated. Confirmation of peri-
menopause relies on medical history and
symptoms. 
The American Association of Clinical
Endocrinologists recommends a detailed
history, exam, and measurement of FSH.
The diagnosis of menopause is confirmed
by FSH levels >40 IU/L; however, they note
in perimenopause, FSH elevation is inter-
mittent and not reliable for establishing the
onset of menopause. ■
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